Crew J - Search Results

1

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.

Blick C, Hall P, Pwint T, Al-Terkait F, Crew J, Powles T, Macaulay V, Munro N, Douglas D, Kilbey N, Protheroe A, Chester JD. Blick C, et al. Among authors: crew j. Cancer. 2012 Aug 15;118(16):3920-7. doi: 10.1002/cncr.26675. Epub 2012 Jan 3. Cancer. 2012. PMID: 22614698 Free article.

2

Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target.

Crew JP, O'Brien TS, Harris AL. Crew JP, et al. Cancer Metastasis Rev. 1996 Jun;15(2):221-30. doi: 10.1007/BF00437475. Cancer Metastasis Rev. 1996. PMID: 8842494 Review.

3

Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer.

Crew JP, O'Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D, Harris AL. Crew JP, et al. Cancer Res. 1997 Dec 1;57(23):5281-5. Cancer Res. 1997. PMID: 9393750

4

High expression of Wnt7b in human superficial bladder cancer vs invasive bladder cancer.

Bui TD, O'Brien T, Crew J, Cranston D, Harris AL. Bui TD, et al. Among authors: crew j. Br J Cancer. 1998;77(2):319-24. doi: 10.1038/bjc.1998.49. Br J Cancer. 1998. PMID: 9461004 Free PMC article.

5

Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression.

Crew JP, Fuggle S, Bicknell R, Cranston DW, de Benedetti A, Harris AL. Crew JP, et al. Br J Cancer. 2000 Jan;82(1):161-6. doi: 10.1054/bjoc.1999.0894. Br J Cancer. 2000. PMID: 10638984 Free PMC article.

6

A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.

Braybrooke JP, O'Byrne KJ, Propper DJ, Blann A, Saunders M, Dobbs N, Han C, Woodhull J, Mitchell K, Crew J, Smith K, Stephens R, Ganesan TS, Talbot DC, Harris AL. Braybrooke JP, et al. Among authors: crew j. Clin Cancer Res. 2000 Dec;6(12):4697-704. Clin Cancer Res. 2000. PMID: 11156222 Clinical Trial.

7

The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer.

Turner KJ, Crew JP, Wykoff CC, Watson PH, Poulsom R, Pastorek J, Ratcliffe PJ, Cranston D, Harris AL. Turner KJ, et al. Among authors: crew jp. Br J Cancer. 2002 Apr 22;86(8):1276-82. doi: 10.1038/sj.bjc.6600215. Br J Cancer. 2002. PMID: 11953885 Free PMC article.

8

Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.

Ord JJ, Streeter E, Jones A, Le Monnier K, Cranston D, Crew J, Joel SP, Rogers MA, Banks RE, Roberts IS, Harris AL. Ord JJ, et al. Among authors: crew j. Br J Cancer. 2005 Jun 20;92(12):2140-7. doi: 10.1038/sj.bjc.6602650. Br J Cancer. 2005. PMID: 15928663 Free PMC article. Clinical Trial.

9

The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer.

Rochester MA, Patel N, Turney BW, Davies DR, Roberts IS, Crew J, Protheroe A, Macaulay VM. Rochester MA, et al. Among authors: crew j. BJU Int. 2007 Dec;100(6):1396-401. doi: 10.1111/j.1464-410X.2007.06931.x. Epub 2007 Jul 23. BJU Int. 2007. PMID: 17645417

10

Automated uro-oncology data collection: the Cancer Research Uro-Oncology Database.

Charlesworth PJ, Kilbey N, Taylor M, Leek R, Cranston D, Turner G, Crew J, Harris A, Protheroe A. Charlesworth PJ, et al. Among authors: crew j. BJU Int. 2010 Jun;105(12):1663-6. doi: 10.1111/j.1464-410X.2009.09058.x. Epub 2009 Nov 20. BJU Int. 2010. PMID: 19930178

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

139 results

Search Page

Filters